<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0042-9686</journal-id>
<journal-title><![CDATA[Bulletin of the World Health Organization]]></journal-title>
<abbrev-journal-title><![CDATA[Bull World Health Organ]]></abbrev-journal-title>
<issn>0042-9686</issn>
<publisher>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0042-96862004000100007</article-id>
<article-id pub-id-type="doi">10.1590/S0042-96862004000100007</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Certification of polio eradication: process and lessons learned]]></article-title>
<article-title xml:lang="fr"><![CDATA[Certification de l'éradication de la poliomyélite: procédure et enseignements]]></article-title>
<article-title xml:lang="es"><![CDATA[Certificación de la erradicación de la poliomielitis: proceso y enseñanzas extraídas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[Joseph]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leke]]></surname>
<given-names><![CDATA[Rose]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[Anthony]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tangermann]]></surname>
<given-names><![CDATA[Rudolf H.]]></given-names>
</name>
<xref ref-type="aff" rid="A04"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Global Polio Certification Commission  ]]></institution>
<addr-line><![CDATA[London ]]></addr-line>
<country>England</country>
</aff>
<aff id="A02">
<institution><![CDATA[,University of Yaoundé Faculty of Medicine Department of Immunology and Microbiology]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cameroon</country>
</aff>
<aff id="A03">
<institution><![CDATA[,National Centre for Epidemiology and Population Health  ]]></institution>
<addr-line><![CDATA[Canberra ]]></addr-line>
<country>Australia</country>
</aff>
<aff id="A04">
<institution><![CDATA[,World Health Organization Department of Immunization, Vaccines and Biologicals ]]></institution>
<addr-line><![CDATA[Geneva ]]></addr-line>
<country>Switzerland</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>01</month>
<year>2004</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>01</month>
<year>2004</year>
</pub-date>
<volume>82</volume>
<numero>1</numero>
<fpage>24</fpage>
<lpage>30</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;pid=S0042-96862004000100007&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_abstract&amp;pid=S0042-96862004000100007&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_pdf&amp;pid=S0042-96862004000100007&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Since the 1988 World Health Assembly resolution to eradicate poliomyelitis, considerable progress has been made towards interrupting the transmission of wild poliovirus globally. A formal process for the certification of polio eradication was established on the basis of experience gained during smallpox eradication. Independent groups of experts were designated at the global, regional, and country levels to conduct the process. The main requirements for the global certification of the eradication of wild poliovirus are the absence of wild poliovirus, isolated from suspect polio cases, healthy individuals, or environmental samples, in all WHO regions for a period of at least three years in the presence of high-quality, certification-standard surveillance and the containment of all wild poliovirus stocks in laboratories. Three WHO regions - the Region of the Americas (1994), Western Pacific Region (2000), and European Region (2002) - have already been certified free of indigenous wild poliovirus. Eradication and certification activities are progressing well in the three endemic regions (African, Eastern Mediterranean, and South-East Asia). Several challenges remain for the certification of polio eradication: the need for even closer coordination of certification activities between WHO regions, the verification of laboratory containment, the development of an appropriate mechanism to verify the absence of circulating vaccine-derived polioviruses in the future, and the maintenance of polio-free status in certified regions until global certification.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[Depuis la résolution de l'Assemblée mondiale de la Santé adoptée en 1988 concernant l'éradication de la poliomyélite, l'interruption de la transmission du poliovirus sauvage a considérablement progressé dans le monde entier. Une procédure formelle de certification a été établie sur la base de l'expérience acquise pour la variole. Des groupes indépendants d'experts ont été désignés aux niveaux mondial, régional et des pays pour mener cette procédure à bien. En matière de certification, les principales exigences sont l'absence constatée du poliovirus sauvage dans des échantillons prélevés sur des cas suspects, sur des sujets en bonne santé ou dans l'environnement, dans toutes les Régions de l'OMS pendant au moins trois années consécutives moyennant une surveillance de grande qualité répondant aux normes de certification, et le confinement de tous les stocks de poliovirus sauvages en laboratoire. Trois Régions de l'OMS - les Amériques (1994), le Pacifique occidental (2000) et la Région européenne (2002) - ont déjà été certifiées exemptes de poliovirus sauvages autochtones. L'éradication et les activités en vue de la certification progressent dans les trois Régions d'endémie (Afrique, Méditerranée orientale et Asie du Sud-Est). Il reste plusieurs défis à relever pour parvenir à la certification : renforcer la coordination des activités de certification entre les Régions de l'OMS, vérifier le confinement des virus en laboratoire, mettre au point un mécanisme pour vérifier à l'avenir que les poliovirus dérivés des souches vaccinales ne circulent pas, maintenir le statut des Régions déjà certifiées jusqu'à la certification mondiale.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Desde la resolución adoptada en 1988 por la Asamblea Mundial de la Salud para erradicar la poliomielitis, los progresos hacia la interrupción de la transmisión del poliovirus salvaje a nivel mundial han sido considerables. Se trazó un proceso formal para certificar la erradicación de la poliomielitis sobre la base de la experiencia adquirida durante la erradicación de la viruela, y se nombraron grupos independientes de expertos a nivel mundial, regional y de país para dirigir el proceso. Los requisitos principales para la certificación mundial de la erradicación del poliovirus salvaje son la ausencia de este poliovirus en casos sospechosos de poliomielitis, individuos sanos o muestras ambientales en todas las regiones de la OMS durante un periodo de al menos tres años, la instauración de una vigilancia de alta calidad conforme con los criterios de certificación, y la contención de todas las reservas de poliovirus salvaje en los laboratorios. Tres Regiones de la OMS - Américas (1994), Pacífico Occidental (2000) y Europa (2002) - ya han sido certificadas como libres del poliovirus salvaje autóctono. La erradicación y las actividades de certificación están progresando satisfactoriamente en las tres regiones endémicas (África, Mediterráneo Oriental y Asia Sudoriental). No obstante, en el camino hacia la certificación de la erradicación quedan todavía algunos obstáculos: la necesidad de una coordinación aún mayor de las actividades de certificación entre las regiones de la OMS, la verificación de la contención en los laboratorios, el desarrollo de un mecanismo apropiado para comprobar la ausencia de poliovirus circulantes de origen vacunal en el futuro, y el mantenimiento de la situación de ausencia de poliomielitis en las regiones certificadas hasta el momento de la certificación mundial.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Poliomyelitis]]></kwd>
<kwd lng="en"><![CDATA[Poliomyelitis]]></kwd>
<kwd lng="en"><![CDATA[Certification]]></kwd>
<kwd lng="en"><![CDATA[Certification]]></kwd>
<kwd lng="en"><![CDATA[Certification]]></kwd>
<kwd lng="en"><![CDATA[Poliovirus]]></kwd>
<kwd lng="en"><![CDATA[Paralysis]]></kwd>
<kwd lng="en"><![CDATA[Epidemiologic surveillance]]></kwd>
<kwd lng="en"><![CDATA[Containment of biohazards]]></kwd>
<kwd lng="en"><![CDATA[World Health Organization]]></kwd>
<kwd lng="fr"><![CDATA[Poliomyélite antérieure aiguë]]></kwd>
<kwd lng="fr"><![CDATA[Poliomyélite antérieure aiguë]]></kwd>
<kwd lng="fr"><![CDATA[Certification]]></kwd>
<kwd lng="fr"><![CDATA[Certification]]></kwd>
<kwd lng="fr"><![CDATA[Certification]]></kwd>
<kwd lng="fr"><![CDATA[Poliovirus humain]]></kwd>
<kwd lng="fr"><![CDATA[Paralysie]]></kwd>
<kwd lng="fr"><![CDATA[Surveillance épidémiologique]]></kwd>
<kwd lng="fr"><![CDATA[Maîtrise risque biologique]]></kwd>
<kwd lng="fr"><![CDATA[Organisation mondiale de la Santé]]></kwd>
<kwd lng="es"><![CDATA[Poliomielitis]]></kwd>
<kwd lng="es"><![CDATA[Poliomielitis]]></kwd>
<kwd lng="es"><![CDATA[Certificación]]></kwd>
<kwd lng="es"><![CDATA[Certificación]]></kwd>
<kwd lng="es"><![CDATA[Certificación]]></kwd>
<kwd lng="es"><![CDATA[Poliovirus]]></kwd>
<kwd lng="es"><![CDATA[Parálisis]]></kwd>
<kwd lng="es"><![CDATA[Vigilancia epidemiológica]]></kwd>
<kwd lng="es"><![CDATA[Contención de riesgos biológicos]]></kwd>
<kwd lng="es"><![CDATA[Organización Mundial de la Salud]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font face="Verdana" size="2"><b>POLICY AND PRACTICE</b></font></p>     <p>&nbsp;</p>     <p><font size="4" face="Verdana"><B><a name="topo"></a>Certification of polio    eradication: process and lessons learned</B></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Certification de l'&eacute;radication de la    poliomy&eacute;lite : proc&eacute;dure et enseignements</b></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Certificaci&oacute;n de la erradicaci&oacute;n    de la poliomielitis: proceso y ense&ntilde;anzas extra&iacute;das</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Sir Joseph Smith<SUP>I</SUP>; Rose Leke<SUP>II</SUP>;    Anthony Adams<SUP>III</SUP>; Rudolf H. Tangermann<SUP>IV,</SUP> <a href="#n1"><SUP>1</SUP></a></b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><SUP>I</SUP>Chair, Global Polio Certification    Commission, London, England    <br>   <SUP>II</SUP>Department of Immunology and Microbiology, Faculty of Medicine,    University of Yaound&eacute;, Cameroon    <br>   <SUP>III</SUP>Professor of Public Health, National Centre for Epidemiology and    Population Health, Canberra, Australia    <br>   <SUP>IV</SUP>Medical Officer, Department of Immunization, Vaccines and Biologicals,    World Health Organization, Geneva, Switzerland (email: <a href="mailto:tangermannr@who.int">tangermannr@who.int</a>)</font></p>      <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font face="Verdana" size="2"><b>ABSTRACT</b></font></p>     <p><font face="Verdana" size="2">Since the 1988 World Health Assembly resolution    to eradicate poliomyelitis, considerable progress has been made towards interrupting    the transmission of wild poliovirus globally. A formal process for the certification    of polio eradication was established on the basis of experience gained during    smallpox eradication. Independent groups of experts were designated at the global,    regional, and country levels to conduct the process. The main requirements for    the global certification of the eradication of wild poliovirus are the absence    of wild poliovirus, isolated from suspect polio cases, healthy individuals,    or environmental samples, in all WHO regions for a period of at least three    years in the presence of high-quality, certification-standard surveillance and    the containment of all wild poliovirus stocks in laboratories. Three WHO regions    &#151; the Region of the Americas (1994), Western Pacific Region (2000), and    European Region (2002) &#151; have already been certified free of indigenous    wild poliovirus. Eradication and certification activities are progressing well    in the three endemic regions (African, Eastern Mediterranean, and South-East    Asia). Several challenges remain for the certification of polio eradication:    the need for even closer coordination of certification activities between WHO    regions, the verification of laboratory containment, the development of an appropriate    mechanism to verify the absence of circulating vaccine-derived polioviruses    in the future, and the maintenance of polio-free status in certified regions    until global certification.</font></p>     <p><font face="Verdana" size="2"><B>Keywords:</B> Poliomyelitis/prevention and    control/diagnosis; Certification/organization and administration/standards/trends;    Poliovirus/growth and development; Paralysis/etiology; Epidemiologic surveillance;    Containment of biohazards; World Health Organization (<I>source: MeSH, NLM</I>).</font></p> <hr size="1" noshade>     <p><font face="Verdana" size="2"><b>R&Eacute;SUM&Eacute;</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Depuis la r&eacute;solution de l'Assembl&eacute;e    mondiale de la Sant&eacute; adopt&eacute;e en 1988 concernant l'&eacute;radication    de la poliomy&eacute;lite, l'interruption de la transmission du poliovirus sauvage    a consid&eacute;rablement progress&eacute; dans le monde entier. Une proc&eacute;dure    formelle de certification a &eacute;t&eacute; &eacute;tablie sur la base de    l'exp&eacute;rience acquise pour la variole. Des groupes ind&eacute;pendants    d'experts ont &eacute;t&eacute; d&eacute;sign&eacute;s aux niveaux mondial,    r&eacute;gional et des pays pour mener cette proc&eacute;dure &agrave; bien.    En mati&egrave;re de certification, les principales exigences sont l'absence    constat&eacute;e du poliovirus sauvage dans des &eacute;chantillons pr&eacute;lev&eacute;s    sur des cas suspects, sur des sujets en bonne sant&eacute; ou dans l'environnement,    dans toutes les R&eacute;gions de l'OMS pendant au moins trois ann&eacute;es    cons&eacute;cutives moyennant une surveillance de grande qualit&eacute; r&eacute;pondant    aux normes de certification, et le confinement de tous les stocks de poliovirus    sauvages en laboratoire. Trois R&eacute;gions de l'OMS &#150; les Am&eacute;riques    (1994), le Pacifique occidental (2000) et la R&eacute;gion europ&eacute;enne    (2002) &#150; ont d&eacute;j&agrave; &eacute;t&eacute; certifi&eacute;es exemptes    de poliovirus sauvages autochtones. L'&eacute;radication et les activit&eacute;s    en vue de la certification progressent dans les trois R&eacute;gions d'end&eacute;mie    (Afrique, M&eacute;diterran&eacute;e orientale et Asie du Sud-Est). Il reste    plusieurs d&eacute;fis &agrave; relever pour parvenir &agrave; la certification    : renforcer la coordination des activit&eacute;s de certification entre les    R&eacute;gions de l'OMS, v&eacute;rifier le confinement des virus en laboratoire,    mettre au point un m&eacute;canisme pour v&eacute;rifier &agrave; l'avenir que    les poliovirus d&eacute;riv&eacute;s des souches vaccinales ne circulent pas,    maintenir le statut des R&eacute;gions d&eacute;j&agrave; certifi&eacute;es    jusqu'&agrave; la certification mondiale.</font></p>     <p><font face="Verdana" size="2"><B>Mots cl&eacute;s: </B> Poliomy&eacute;lite    ant&eacute;rieure aigu&euml;/pr&eacute;vention et contr&ocirc;le/diagnostic;    Certification/organisation et administration/normes/orientations; Poliovirus    humain/croissance et d&eacute;veloppement; Paralysie/&eacute;tiologie; Surveillance    &eacute;pid&eacute;miologique; Ma&icirc;trise risque biologique; Organisation    mondiale de la Sant&eacute; (<I>source: MeSH, INSERM</I>).</font></p> <hr size="1" noshade>     <p><font face="Verdana" size="2"><b>RESUMEN</b></font></p>     <p><font face="Verdana" size="2">Desde la resoluci&oacute;n adoptada en 1988 por    la Asamblea Mundial de la Salud para erradicar la poliomielitis, los progresos    hacia la interrupci&oacute;n de la transmisi&oacute;n del poliovirus salvaje    a nivel mundial han sido considerables. Se traz&oacute; un proceso formal para    certificar la erradicaci&oacute;n de la poliomielitis sobre la base de la experiencia    adquirida durante la erradicaci&oacute;n de la viruela, y se nombraron grupos    independientes de expertos a nivel mundial, regional y de pa&iacute;s para dirigir    el proceso. Los requisitos principales para la certificaci&oacute;n mundial    de la erradicaci&oacute;n del poliovirus salvaje son la ausencia de este poliovirus    en casos sospechosos de poliomielitis, individuos sanos o muestras ambientales    en todas las regiones de la OMS durante un periodo de al menos tres a&ntilde;os,    la instauraci&oacute;n de una vigilancia de alta calidad conforme con los criterios    de certificaci&oacute;n, y la contenci&oacute;n de todas las reservas de poliovirus    salvaje en los laboratorios. Tres Regiones de la OMS - Am&eacute;ricas (1994),    Pac&iacute;fico Occidental (2000) y Europa (2002) - ya han sido certificadas    como libres del poliovirus salvaje aut&oacute;ctono. La erradicaci&oacute;n    y las actividades de certificaci&oacute;n est&aacute;n progresando satisfactoriamente    en las tres regiones end&eacute;micas (&Aacute;frica, Mediterr&aacute;neo Oriental    y Asia Sudoriental). No obstante, en el camino hacia la certificaci&oacute;n    de la erradicaci&oacute;n quedan todav&iacute;a algunos obst&aacute;culos: la    necesidad de una coordinaci&oacute;n a&uacute;n mayor de las actividades de    certificaci&oacute;n entre las regiones de la OMS, la verificaci&oacute;n de    la contenci&oacute;n en los laboratorios, el desarrollo de un mecanismo apropiado    para comprobar la ausencia de poliovirus circulantes de origen vacunal en el    futuro, y el mantenimiento de la situaci&oacute;n de ausencia de poliomielitis    en las regiones certificadas hasta el momento de la certificaci&oacute;n mundial.</font></p>     <p><font face="Verdana" size="2"><B>Palabras clave:</B>Poliomielitis/prevenci&oacute;n    y control/diagn&oacute;stico; Certificaci&oacute;n/organizaci&oacute;n e administraci&oacute;n/normas/tendencias;    Poliovirus/crecimiento y desarrollo; Par&aacute;lisis/etiolog&iacute;a; Vigilancia    epidemiol&oacute;gica; Contenci&oacute;n de riesgos biol&oacute;gicos; Organizaci&oacute;n    Mundial de la Salud (<I>fuente: DeCS, BIREME</I>).</font></p> <hr size="1" noshade>     <p align="center"><img src="/img/revistas/bwho/v82n1/1a06.gif"></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Introduction</b></font></p>     <p><font face="Verdana" size="2">Since the 1988 World Health Assembly resolution    to eradicate poliomyelitis (<I>1</I>), considerable progress has been made towards    interrupting the transmission of wild poliovirus globally. The number of polio-endemic    countries worldwide has fallen from over 125 in 1988 to only seven countries    in three WHO regions at the end of 2002 (<I>2</I>). A formal process for the    certification of polio eradication was established on the basis of experience    gained during smallpox eradication. Independent groups of experts were designated    at global, regional, and country levels to set criteria and conduct the certification    process. Three WHO regions have already been certified free of indigenous wild    poliovirus &#151; Region of the Americas (AMR) (1994), (<I>3</I>) Western Pacific    Region (WPR) (2000), (<I>4</I>) and European Region (EUR) (2002) (<I>5</I>).    Eradication and certification activities are progressing well in the three remaining    endemic WHO regions (African Region (AFR); Eastern Mediterranean Region (EMR);    and South-East Asia Region (SEAR).</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">The present report describes the development    and current status of the process used to certify the eradication of indigenous    wild poliovirus, highlights the lessons learned, and outlines the challenges    faced in achieving global certification and for the post certification era.</font></p>     <p><font face="Verdana" size="2"><B>Basis for the global certification process</B></font></p>     <p><font face="Verdana" size="2">The concept of independent external verification    and certification of eradication now followed by the polio eradication initiative    was initially applied to smallpox eradication (<I>6</I>) &#151; the unprecedented    global effort that eradicated the causative agent of a human infectious disease    for the first time. To ensure global credibility, an international smallpox    certification commission of experts was appointed by Dr Halfdan Mahler, then    Director-General of WHO. This commission undertook field visits to all previously    endemic countries, and after close scrutiny of all available epidemiological    data, it certified in December 1979 that smallpox had been eradicated globally    (<I>6</I>).</font></p>     <p><font face="Verdana" size="2">In the light of this success, AMR was the first    WHO region to initiate a regional polio eradication initiative in 1985. But,    owing to the many inapparent infections (&gt;99% of wild poliovirus infections    do not cause paralytic disease) and the relatively non-specific initial clinical    picture of paralytic polio, it was clear that surveillance and certification    activities would be more challenging than for smallpox eradication.</font></p>     <p><font face="Verdana" size="2">On the basis of the smallpox experience, an independent    International Commission for the Certification of Poliomyelitis Eradication    in AMR was appointed by the Director of the Pan-American Health Organization    in 1990 to evaluate the progress of the initiative and to certify, if and when    it judged appropriate, that transmission of indigenous wild poliovirus had been    interrupted in the entire region (<I>7</I>). National Certification Committees    (NCCs) were formed in each country to oversee certification procedures nationally    and to prepare and submit a final report, claiming polio-free status, to the    International Commission. The last known confirmed polio case due to wild virus    in AMR occurred in Peru in 1991. Three years later (<I>8</I>), during which    high-quality surveillance was maintained in countries that were endemic or recently    endemic at the beginning of the initiative, the International Commission certified    AMR to be free of indigenous wild poliovirus transmission (<I>9</I>).</font></p>     <p><font face="Verdana" size="2">The World Health Assembly recognized the progress    made in AMR and resolved in 1988 to eradicate polio globally (<I>1</I>), initiating    eradication activities in all other WHO regions.</font></p>     <p><font face="Verdana" size="2"><B>Principles and criteria for global certification</B></font></p>     <p><font face="Verdana" size="2">A Global Commission for the Certification of    the Eradication of Poliomyelitis (GCC) was appointed by Dr Hiroshi Nakajima,    then Director-General of WHO, in 1995 to oversee polio eradication certification    activities at the global level. The GCC, at its first meeting, established basic    definitions, principles, and criteria upon which certification would be based,    and defined the terms of reference and operating procedures of certification    bodies at regional and country levels. Regional Certification Commissions (RCCs)    were then established and began to function in all other WHO regions: 1995 in    EMR, 1996 in EUR and WPR, 1997 in SEAR, and 1998 in AFR. By May 2003, NCCs had    been established in all WHO Member States globally except Monaco and San Marino    (EUR), Somalia (EMR), and Timor-Leste (SEAR).</font></p>     <p><font face="Verdana" size="2"><B><I>Definition of eradication</I></B></font></p>     <p><font face="Verdana" size="2">During its first meeting (<I>10</I>), the GCC    defined global polio eradication as "the eradication of all wild polioviruses",    and specified that "the occurrence of clinical cases of poliomyelitis caused    by other enteroviruses, including attenuated polio vaccine viruses, does not    invalidate the achievement of wild poliovirus eradication".</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Following the detection of an outbreak of paralytic    poliomyelitis caused by circulating vaccine-derived poliovirus (cVDPV) on Hispaniola    island (<I>11</I>), the GCC re-emphasized that the objective of its work was    to certify the eradication of wild poliovirus, including completion of the containment    process (<I>12</I>). The GCC recognized, however, that the full benefits of    polio eradication would only be realized in the absence of cVDPV, and requested    WHO to develop a separate process for verifying the absence of cVDPV in the    post-certification era, after cessation of oral poliovirus vaccine use.</font></p>     <p><font face="Verdana" size="2">In certifying their region as polio-free, RCCs    &#151; first in AMR, then in WPR and EUR &#151; have been careful to limit themselves    to certifying the absence of indigenous wild poliovirus, because of the possibility    of wild virus importation from remaining endemic regions, and because laboratory    containment of wild poliovirus has not yet been completed in any region.</font></p>     <p><font face="Verdana" size="2"><B><I>Criteria for certification</I></B></font></p>     <p><font face="Verdana" size="2">The main criteria set by the GCC as prerequisites    for global polio-free certification were to show first, the absence of wild    poliovirus, isolated from cases of acute flaccid paralysis (AFP) (suspect polio),    healthy individuals, or environmental samples, in all WHO regions for a period    of at least three years in the presence of high-quality, certification-standard    surveillance (<I>10</I>) and second, the containment of all wild poliovirus    stocks in laboratories through completion of the requirements of the <I>WHO    global action plan for laboratory containment of wild polioviruses</I> (<I>13</I>).</font></p>     <p><font face="Verdana" size="2"><B>Certification-standard surveillance</B></font></p>     <p><font face="Verdana" size="2">The GCC stressed the importance of maintaining,    especially in all recently and currently endemic countries, the sensitivity    of surveillance for AFP cases at levels that enable the detection, rapid reporting,    and investigation of any paralytic polio cases. To reach "certification standard",    AFP surveillance systems need to first detect at least one case of non-polio    AFP per 100 000 population aged less than 15 years annually; second, collect    two adequate stool specimens<a name="an"></a><a href="#na"><SUP>a</SUP></a>    from at least 80% of AFP cases; and third, test all stool specimens for poliovirus    at a WHO-accredited laboratory (<I>14</I>).</font></p>     <p><font face="Verdana" size="2">The GCC defined additional criteria that should    also be used when assessing whether or not AFP surveillance quality meets certification    standard: first, documentation of the timely receipt of at least 80% of expected    routine surveillance reports, including "ZERO" reports, where no AFP cases were    seen; second, investigation of 80% of AFP cases within 48 hours of the initial    report; third, detailed clinical, epidemiological, and virological investigation,    follow-up examination 60 days after onset, and final case classification of    all AFP cases by a committee of experts. Although these additional checks are    important, surveillance quality will not "fail" if one or two of these are just    below the cut-off.</font></p>     <p><font face="Verdana" size="2">Although the GCC considered AFP surveillance    as the "gold standard" for countries that were endemic or recently endemic for    poliovirus at the beginning of the eradication initiative in 1988, other surveillance    strategies and data have been accepted from countries that have been non-endemic    for a long time, with high levels of sanitation and strong health systems. Alternative    surveillance strategies and data accepted from such non-endemic countries include    combinations of the following: surveillance for "poliomyelitis cases" and for    cases of vaccine-associated paralytic poliomyelitis (VAPP); enterovirus surveillance;    and/or environmental surveillance for polioviruses.</font></p>     <p><font face="Verdana" size="2">The GCC determined that, as opposed to smallpox    eradication, certification would not occur by country but that only WHO regions    as a whole would be certified polio-free. Every country and area in the region    would need to provide evidence that no indigenous wild poliovirus had been isolated    for at least three years, under conditions of certification-standard AFP surveillance.</font></p>     <p><font face="Verdana" size="2"><B>Laboratory containment of wild poliovirus</B></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">In addition to interrupting the transmission    of wild poliovirus in human populations, the only natural poliovirus reservoir,    polio eradication will not be complete without laboratory containment &#151;    minimizing the risk of reintroduction of wild poliovirus into the community    from a laboratory.</font></p>     <p><font face="Verdana" size="2">Beginning in 1997 (<I>15</I>), the GCC supported    the development of principles and processes for laboratory containment through    international consultation. In 1998, the GCC approved the resulting <I>WHO global    action plan for laboratory containment of wild polioviruses</I> (<I>13</I>),    which comprises three phases: phase 1, laboratory survey and inventory; phase    2, global certification; and phase 3, post-global certification. The containment    needs for inactivated polio vaccine production sites are addressed by separately    published WHO guidelines (<I>16</I>).</font></p>     <p><font face="Verdana" size="2">The GCC decided at its third meeting that for    regional certification to occur, all countries needed to provide evidence that    the activities described in phase 1 of the global containment action plan had    been implemented (<I>17</I>). Phase 1 comprised recommendations for the implementation    of biosafety level (BSL)-/2 polio procedures in enterovirus laboratories, completion    of a national inventory of laboratories/facilities holding materials containing    or possibly containing wild polioviruses, and establishment of a plan of action    for either destroying or moving such materials to a "high containment facility"    during phase 2. Global certification will require that phase 2 containment activities,    to begin one year after wild poliovirus was last isolated, have been implemented    worldwide (destruction of all unneeded wild poliovirus materials, and implementation    of appropriate biosafety measures &#151; BSL-2/polio or BSL-3/polio &#151; for    all materials retained or transferred to a WHO-designated repository). All RCCs    are currently working to fully align certification and containment activities,    involving NCCs in the oversight of national containment activities and requiring    them to report regularly on progress achieved.</font></p>     <p><font face="Verdana" size="2">Containment had not been part of eradication    and certification activities in AMR, and not all countries in WPR and EUR had    fully implemented phase 1 containment activities at the time of regional certification.    Nevertheless, considerable progress has been made, particularly in the certified    regions (<I>2</I>). By May 2003, 155 of 207 non-endemic countries globally had    established a national containment task force and national containment plans    of action. By the end of 2002, 149 WHO Member States had initiated national    laboratory surveys. Of those, 79 countries had completed and submitted an inventory    of facilities holding wild virus infectious or potentially infectious materials.    The countries comprised 41 of 51 countries in EUR, 33 of 36 in WPR, and 5 of    23 EMR countries. In AMR, laboratory surveys are ongoing in 19 of 48 countries    of the region.</font></p>     <p><font face="Verdana" size="2"><B>Composition and terms of reference of certification    groups</B></font></p>     <p><font face="Verdana" size="2">The Director-General of WHO in 1995 charged the    GCC with three tasks: first, defining the parameters and processes by which    polio eradication will be certified, guiding regions and countries in establishing    their data collection processes; second, receiving and reviewing the final reports    of RCCs of polio eradication; and third, issuing, if and when appropriate, a    final report to the Director-General of WHO certifying that global polio eradication    had been achieved.</font></p>     <p><font face="Verdana" size="2">The GCC has continued to meet annually since    1995 to review progress in regional certification and to provide continued guidance    to regions and countries. The GCC closely follows the deliberations of the Global    Technical Consultative Group for Polio Eradication (global TCG) &#151; with    GCC members attending TCG meetings &#151; to remain abreast of the latest developments    in polio eradication globally and of key emerging technical issues bearing on    certification and surveillance.</font></p>     <p><font face="Verdana" size="2">RCCs (<a href="/img/revistas/bwho/v82n1/1a06f01.gif">Fig. 1</a>)    are appointed by the Regional Directors of each WHO region and should include    members of the GCC who are from the region (usually the RCC chairperson) as    well as representatives of other WHO regions. After a three-year period of freedom    from indigenous wild poliovirus transmission under conditions of certification-quality    surveillance, and considering all necessary evidence, including the views of    NCCs and results of field visits to countries, RCCs have the authority to certify    the eradication of indigenous wild poliovirus in the region.</font></p>     <p><font face="Verdana" size="2">NCCs are responsible for assessing and verifying    national documentation on polio-free status, which is collected and provided    by the national ministry of health secretariat. NCCs cannot certify polio eradication    in their own country, but present their opinion, with supporting documentation,    for assessment by the RCC. The GCC has decided that UN polio partner agencies    (WHO; United Nations Children's Fund, UNICEF) will support data collection and    verification mechanisms for certification in countries or areas without internationally    recognized governments.</font></p>     <p><font face="Verdana" size="2">The GCC stated that members of both RCCs and    NCCs should be independent leading experts in relevant disciplines such as public    health, epidemiology, virology, and clinical medicine. Members should have no    direct responsibility for polio eradication or immunization programmes in their    country or region, act in their personal capacity only, and understand that    their scientific reputations will rest on their judgements concerning polio    eradication.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">The work of the GCC will become increasingly    crucial as the polio-free certification of the last WHO region approaches, with    global certification following soon thereafter. Following the certification    of the last WHO region, the GCC will request final update documentation from    all RCCs in order to assess whether freedom from wild virus has indeed been    maintained everywhere &#151; and, in turn, whether global eradication has been    achieved.</font></p>     <p><font face="Verdana" size="2"><B>Operating principles and certification process</B></font></p>     <p><font face="Verdana" size="2">All RCCs prepared a regional "plan of action"    for certification, with a proposed timetable of activities. RCCs have often    adopted a phased approach to review epidemiological blocks within the Region,    based on the often widely different endemicity status of countries in the Region    when the initiative began. For example, the RCCs in both WPR and EUR reviewed    non endemic countries before turning to recently endemic countries. RCCs work    through regular annual or semi-annual meetings with selected NCCs, which often    also include national polio eradication and/or WHO staff as observers. After    an initial phase of briefing newly established NCCs, RCC meetings focus increasingly    on a review of selected countries through presentations by the respective NCC    chairperson. Initially, these reports are updates on the polio situation in    a country, but, once eligible, NCCs are asked to present "final national documentation"    claiming polio-free status for consideration by the RCC.</font></p>     <p><font face="Verdana" size="2">In addition to receiving NCC reports, RCC members,    particularly in the EUR and WPR, have conducted visits to selected countries,    and used other sources of information (i.e. reports of AFP surveillance reviews,    consultant assessments, the UN, and nongovernmental organization team reports    from areas not recognized internationally) to broaden their information base    about particular countries and areas.</font></p>     <p><font face="Verdana" size="2">Countries become eligible to present final national    documentation after three years have passed without isolating indigenous strains    of wild poliovirus in the country, under conditions of certification-standard    surveillance. NCCs were established long before the end of a three-year polio-free    interval in many countries that were endemic or recently endemic at the beginning    of regional eradication efforts. Therefore, the finalization of country documentation    on polio-free status in most countries is a multi year, iterative process, involving    repeated dialogue between the NCCs and the RCC.</font></p>     <p><font face="Verdana" size="2">Although both the RCC and the NCCs were dissolved    in AMR after regional certification, most countries that were endemic or recently    endemic at the beginning of the regional initiative have maintained sensitive    AFP surveillance systems, with many countries continuing to conduct annual national    immunization days (NIDs). The GCC has subsequently decided that both RCCs and    NCCs should continue to function in regions certified as polio-free until global    eradication is declared, in order to oversee and support continued country activities    to maintain polio-free status as well as containment measures. Accordingly,    regional and national certification bodies have been maintained in both WPR    and EUR.</font></p>     <p><font face="Verdana" size="2"><B>National documentation</B></font></p>     <p><font face="Verdana" size="2">Each RCC, guided by the GCC, prepared standardized    modules for the submission of national documentation for certification, to be    assembled by national "secretariats" (national immunization programmes), reviewed    and verified by NCCs, and eventually presented to RCCs. The national documentation    required by RCCs varies depending on regional circumstances. However, key categories    of national documentation are:</font></p> <ul>       <li><font face="Verdana" size="2">country background information (demography,      population distribution, high-risk groups, migration patterns, health care      systems, etc.);</font></li>       <li><font face="Verdana" size="2">structure and responsibilities of national      units concerned with polio eradication;</font></li>       ]]></body>
<body><![CDATA[<li><font face="Verdana" size="2">confirmed polio cases and polio-compatible      cases;</font></li>       <li><font face="Verdana" size="2">surveillance activities, including AFP surveillance      quality;</font></li>       <li><font face="Verdana" size="2">information about the polio laboratories serving      the country, including documentation of the results of WHO accreditation;</font></li>       <li><font face="Verdana" size="2">progress towards laboratory containment;</font></li>       <li><font face="Verdana" size="2">a plan of action for handling wild poliovirus      importations, including their detection, investigation, and intended response      procedures;</font></li>       <li><font face="Verdana" size="2">routine and supplementary immunization activities.</font></li>     </ul>     <p><font face="Verdana" size="2">The national documentation format used in all    regions has included pre-formatted tables, checklists and "yes/ no" questions.    This has proved helpful to country teams and NCCs, particularly early on in    the certification process.</font></p>     <p><font face="Verdana" size="2">As certification groups gained more experience,    RCCs in WPR and EUR introduced more flexible documentation formats, which required    NCCs to provide more of their own assessments and interpretation of the data    in narrative format. In all certified regions, final RCC reports were supported    by concise "executive summaries", in which NCCs outlined the main reasons to    support their claim of polio-free status.</font></p>     <p><font face="Verdana" size="2"><B>Experience and current status in certified    regions</B></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><i><b>Region of the Americas</b></i></font></p>     <p><font face="Verdana" size="2">On 20 August 1994, the Pan-American Health Organization    reported that three years had passed since the occurrence of the last case of    poliomyelitis associated with wild poliovirus isolation in AMR (<I>7</I>) (Peru,    August 1991). Following certification, both the RCC and country-level NCCs were    dissolved. There are currently no independent groups monitoring activities to    sustain polio-free status at a country or regional level. However, through efforts    by countries and monitoring and follow-up by WHO, good-quality AFP surveillance    has been maintained in most countries of the region that were endemic or recently    endemic at the beginning of the initiative. Laboratory containment had not yet    been a certification requirement when AMR was certified. However, country and    regional containment activities began in 2001, including the designation of    expert groups at regional and country levels.</font></p>     <p><font face="Verdana" size="2"><B><I>Western Pacific Region</I></B></font></p>     <p><font face="Verdana" size="2">On 29 October 2000, the RCC, WPR certified that    WPR, which comprises 37 countries and territories with an estimated population    of 1.6 billion (27% of the world's population), was polio-free (<I>18</I>).    The last known polio case associated with indigenous wild poliovirus occurred    in Cambodia in March 1997 in a 15-month-old girl. NCCs, with a sub-regional    committee for Pacific Island countries, remain active. The RCC and NCCs continue    to conduct regular meetings to help sustain polio-free status in the Region.    As at May 2003, phase 1 laboratory containment activities were complete in all    countries except Japan and China.</font></p>     <p><font face="Verdana" size="2"><B><I>European Region</I></B></font></p>     <p><font face="Verdana" size="2">On 21 June 2002, the RCC, EUR certified the region    as polio-free. The last known polio case caused by indigenous wild poliovirus    occurred in south-east Turkey in November 1998. EUR comprises 51 countries with    an estimated population of 873 million. Importations of wild poliovirus were    documented into Bulgaria and Georgia in 2001, but did not delay regional certification,    because of the high-quality immunization response and because of strong evidence    that the importations had not led to re-established wild poliovirus transmission.    At the time of certification, phase 1 laboratory containment activities were    completed in 41 of 51 countries, and nearly completed in four other countries.</font></p>     <p><font face="Verdana" size="2"><B>Current status of endemic regions</B></font></p>     <p><font face="Verdana" size="2">Although the first priority for polio eradication    teams in endemic regions is to interrupt wild poliovirus transmission, all three    regions have made considerable progress in establishing the certification process.    NCCs have been established in all EMR countries except Somalia, for which WHO/UNICEF    will facilitate certification activities. NCCs in 16 of 22 EMR countries have    started to report to the RCC; final national documentation claiming polio-free    status has been provisionally accepted from nine countries. Seven countries,    including four endemic countries plus Djibouti, Libyan Arab Jamahiriya, and    Sudan, have not yet started reporting to the RCC. Phase 1 laboratory containment    activities have been completed in five countries and containment activities    initiated in 11 others.</font></p>     <p><font face="Verdana" size="2">In SEAR, Timor-Leste is the only country without    an NCC, but certification activities will begin soon. Full national documentation    has been reviewed from Sri Lanka and Thailand &#151; both of which have been    without wild poliovirus for more than three years, in the presence of certification-standard    surveillance. Bangladesh and Nepal will be the next countries to present full    national documentation.</font></p>     <p><font face="Verdana" size="2">Certification activities in AFR began in 1998.    The RCC continues to systematically train and orient NCCs in the 46 AFR member    states, a number of which were established only recently. The RCC is also beginning    to conduct country visits to gather information and to advocate for improvements    in surveillance and supplementary immunization. Containment activities have    begun in two pilot countries &#151; Cameroon and Uganda &#151; in 2003.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><B>Lessons learned and future challenges</B></font></p>     <p><font face="Verdana" size="2">Activities to certify the eradication of wild    poliovirus are essential components of the global polio eradication initiative    and have been very successful. The fact that no indigenous wild virus has been    found post-certification in any of the certified regions, including AMR, for    almost 10 years after regional certification, despite continued high-quality    AFP surveillance, is evidence of the soundness of the certification strategies.</font></p>     <p><font face="Verdana" size="2">The main elements of success have been the application,    and further development by the GCC and RCCs, of lessons learned from smallpox    eradication and polio eradication in AMR, as well as the integration of newly    recognized important programme elements, such as wild poliovirus laboratory    containment.</font></p>     <p><font face="Verdana" size="2">Certification activities are possible only through    the continued commitment from national governments and ministries of health    in all countries, as well as through the support of hundreds of scientists and    public health experts donating their time to work together in certification    groups. Although passionate about contributing to the overall goal of global    eradication, certification group members are fully aware that the optimal way    for them to contribute is to work constructively with national and WHO teams,    from a strictly neutral, independent, and critical position.</font></p>     <p><font face="Verdana" size="2">Several challenges for certification remain.    Not all NCCs in the remaining endemic regions have attained the high level of    expertise needed to critically assess and verify data provided to them by the    programme secretariat. RCCs need to work even more closely to scrutinize cross-regional    data in areas where polio epidemiological blocks belong to more than one WHO    region (e.g. the Horn of Africa). Efficient coordination of certification activities    across regions will require regular cross-participation in RCC meetings, and    possibly joint meetings. More work is needed to develop appropriate tools for    the verification of reported achievements in laboratory containment. The GCC    also noted that mechanisms are required in the future to independently verify    the absence of circulating vaccine-derived polioviruses. Certified regions,    where both sensitive AFP surveillance systems and some supplementary immunization    activities need to continue in order to sustain polio-free status, have already    had to face the problem of a sudden decrease in interest and support from national    governments following regional certification. RCCs and NCCs can play an important    role in sustaining the quality of surveillance and maintaining the necessary    immunity levels until global certification and beyond. Finally, certification    groups need to consider what, if any, additional information will be required    to allow eventual global certification once all six WHO regions are certified    polio-free and phase 2 laboratory containment is achieved everywhere. <img src="/img/revistas/bwho/v82n1/quad.gif"></font></p>     <p><font face="Verdana" size="2"><B>Conflicts of interest:</B> none declared.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>References</b></font></p>     <!-- ref --><p><font face="Verdana" size="2">1. World Health Assembly. <I>Polio eradication    by the year 2000. Resolutions of the 41st World Health Assembly</I>. Geneva:    World Health Organization; 1988 (WHA Resolution no. 41.28).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126276&pid=S0042-9686200400010000700001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">2. Progress towards global eradication of poliomyelitis,    2002. <I>Weekly Epidemiological Record</I> 2003;78:138-44.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126277&pid=S0042-9686200400010000700002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">3. Certification of poliomyelitis eradication    &#151; the Americas, 1994. <I> MMWR. Morbidity and Mortality Weekly Report </I>1994;43:720-2.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126278&pid=S0042-9686200400010000700003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">4. Certification of poliomyelitis eradication    &#151; Western Pacific Region, October 2000. <I>MMWR. Morbidity and Mortality    Weekly Report </I> 2001;50:1-3.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126279&pid=S0042-9686200400010000700004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">5. Certification of poliomyelitis eradication    &#151; European Region. <I>MMWR. Morbidity and Mortality Weekly Report </I>2002;51:572-4.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126280&pid=S0042-9686200400010000700005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">6. Breman JG, Arita I. The confirmation and maintenance    of smallpox eradication. <I>New England Journal of Medicine </I>1980;303:1263-73.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126281&pid=S0042-9686200400010000700006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">7. Expanded programme on immunization. Certification    of poliomyelitis eradication &#151; the Americas, 1994. <I>Weekly Epidemiological    Record</I> 1994;69:293-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126282&pid=S0042-9686200400010000700007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">8. Debanne SM, Rowland DY. Statistical certification    of eradication of poliomyelitis in the Americas. <I>Mathematical Biosciences</I>    1998;150:83-103.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126283&pid=S0042-9686200400010000700008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">9. Robbins FC, de Quadros CA. The certification    of eradication of indigenous poliovirus from the Americas. <I>JAMA </I>1996;275:224-9.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126284&pid=S0042-9686200400010000700009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">10. <I> Report of the 1st meeting of the Global    Commission for the Certification of the Eradication of Poliomyelitis</I>. Geneva:    World Health Organization; 1995. WHO document WHO/EPI/GEN/95.6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126285&pid=S0042-9686200400010000700010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">11. Kew O, Morris-Glasgow V, Landaverde M, Burns    C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated    with circulating type 1 vaccine-derived poliovirus. <I>Science</I> 2002;296:356-9.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126286&pid=S0042-9686200400010000700011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">12. <I> Report of the 6th meeting of the Global    Commission for the Certification of the Eradication of Poliomyelitis</I>. Geneva:    World Health Organization; 2001. WHO document WHO/V&amp;B/01.15.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126287&pid=S0042-9686200400010000700012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">13. <I> WHO Global action plan for laboratory    containment of wild polioviruses</I>, 2nd ed. Geneva: World Health Organization;    2003.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126288&pid=S0042-9686200400010000700013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">14. Acute flaccid paralysis (AFP) surveillance:    the surveillance strategy for poliomyelitis eradication. <I>Weekly Epidemiological    Record</I> 1998;73:113-4.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126289&pid=S0042-9686200400010000700014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">15. <I> Report of the 2nd meeting of the Global    Commission for the Certification of the Eradication of Poliomyelitis. </I>Geneva:    World Health Organization; 1997. WHO document WHO/EPI/GEN/98.03.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126290&pid=S0042-9686200400010000700015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">16. <I> Guidelines for the safe production and    quality control of IPV manufactured from wild polioviruses</I>. Geneva: World    Health Organization (forthcoming).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126291&pid=S0042-9686200400010000700016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">17. <I> Global eradication of poliomyelitis.    Report of the 3rd meeting of the Global Commission for the certification of    the eradication of polio</I>. Geneva: World Health Organization; 1998. WHO document    WHO/EPI/GEN/98.17.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126292&pid=S0042-9686200400010000700017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">18. Adams AI. Farewell to polio in the Western    Pacific. Editorial. <I>Bulletin of the World Health Organization</I> 2000;78:1375.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=126293&pid=S0042-9686200400010000700018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>&nbsp;</p>     <p>&nbsp;</p>        <p><font face="Verdana" size="2"><I>Submitted: 13 June 03     <br>   Final revised version received: 8 September 03     ]]></body>
<body><![CDATA[<br>   Accepted: 30 September 03</I></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><a name="n1"></a><a href="#topo">1</a> Correspondence    should be sent to this author.    <br>   <a name="na"></a><a href="#an">a</a> Stool specimens are considered "adequate"    (allowing an accredited laboratory to detect poliovirus, if present, with sufficient    sensitivity) if two specimens are collected 24 hours apart within 14 days of    onset of paralysis, arriving in the laboratory in good condition (with ice present).</font></p>       ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Assembly</collab>
<source><![CDATA[Polio eradication by the year 2000: Resolutions of the 41st World Health Assembly]]></source>
<year>1988</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Progress towards global eradication of poliomyelitis]]></article-title>
<source><![CDATA[Weekly Epidemiological Record]]></source>
<year>2002</year>
<month>20</month>
<day>03</day>
<volume>78</volume>
<page-range>138-44</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Certification of poliomyelitis eradication - the Americas]]></article-title>
<source><![CDATA[MMWR. Morbidity and Mortality Weekly Report]]></source>
<year>1994</year>
<month>19</month>
<day>94</day>
<volume>43</volume>
<page-range>720-2</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Certification of poliomyelitis eradication: Western Pacific Region]]></article-title>
<source><![CDATA[MMWR. Morbidity and Mortality Weekly Report]]></source>
<year>Octo</year>
<month>be</month>
<day>r </day>
<volume>50</volume>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Certification of poliomyelitis eradication: European Region]]></article-title>
<source><![CDATA[MMWR. Morbidity and Mortality Weekly Report]]></source>
<year>2002</year>
<volume>51</volume>
<page-range>572-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Breman]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Arita]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The confirmation and maintenance of smallpox eradication]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>1980</year>
<volume>303</volume>
<page-range>1263-73</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Expanded programme on immunization: Certification of poliomyelitis eradication - the Americas, 1994]]></article-title>
<source><![CDATA[Weekly Epidemiological Record]]></source>
<year>1994</year>
<volume>69</volume>
<page-range>293-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debanne]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Rowland]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Statistical certification of eradication of poliomyelitis in the Americas]]></article-title>
<source><![CDATA[Mathematical Biosciences]]></source>
<year>1998</year>
<volume>150</volume>
<page-range>83-103</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robbins]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[de Quadros]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The certification of eradication of indigenous poliovirus from the Americas]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1996</year>
<volume>275</volume>
<page-range>224-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<source><![CDATA[Report of the 1st meeting of the Global Commission for the Certification of the Eradication of Poliomyelitis]]></source>
<year>1995</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kew]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Morris-Glasgow]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Landaverde]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garib]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus]]></article-title>
<source><![CDATA[Science]]></source>
<year>2002</year>
<volume>296</volume>
<page-range>356-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<source><![CDATA[Report of the 6th meeting of the Global Commission for the Certification of the Eradication of Poliomyelitis]]></source>
<year>2001</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<source><![CDATA[WHO Global action plan for laboratory containment of wild polioviruses]]></source>
<year>2003</year>
<edition>2</edition>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Acute flaccid paralysis (AFP) surveillance: the surveillance strategy for poliomyelitis eradication]]></article-title>
<source><![CDATA[Weekly Epidemiological Record]]></source>
<year>1998</year>
<volume>73</volume>
<page-range>113-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<source><![CDATA[Report of the 2nd meeting of the Global Commission for the Certification of the Eradication of Poliomyelitis]]></source>
<year>1997</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<source><![CDATA[Guidelines for the safe production and quality control of IPV manufactured from wild polioviruses]]></source>
<year></year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<source><![CDATA[Global eradication of poliomyelitis: Report of the 3rd meeting of the Global Commission for the certification of the eradication of polio]]></source>
<year>1998</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Farewell to polio in the Western Pacific: Editorial]]></article-title>
<source><![CDATA[Bulletin of the World Health Organization]]></source>
<year>2000</year>
<volume>78</volume>
<page-range>1375</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
